TY - JOUR
T1 - Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma
T2 - Subgroup analysis in Japanese patients from a randomized, double-blind phase II study
AU - Tomita, Yoshihiko
AU - Fukasawa, Satoshi
AU - Oya, Mototsugu
AU - Uemura, Hirotsugu
AU - Shinohara, Nobuo
AU - Habuchi, Tomonori
AU - Rini, Brian I.
AU - Chen, Ying
AU - Bair, Angel H.
AU - Ozono, Seiichiro
AU - Naito, Seiji
AU - Akaza, Hideyuki
N1 - Funding Information:
This study was sponsored by Pfizer. Pfizer was involved in study design, data collection and interpretation of data. We thank Hisanaga Ohashi of Pfizer for data collection and Hiroko Godai of Pfizer for data analysis. Medical writing support was provided by Mariko Nagashima, PhD, of Engage Scientific Solutions (Southport, CT, USA) and was funded by Pfizer.
Publisher Copyright:
© The Author 2016. Published by Oxford University Press. All rights reserved.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Objectives: To conduct Japanese subgroup analyses of a randomized, global Phase II study of axitinib with and without dose titration in first-line metastatic renal cell carcinoma and to explore predictive factors for axitinib efficacy in first-line metastatic renal cell carcinoma. Methods: The data included 44 Japanese and 169 non-Japanese treatment-naïve patients with metastatic renal cell carcinoma. Patients received twice-daily axitinib 5mg during a 4-week lead-in period. Patients who met the pre-defined randomization criteria were stratified by Eastern Cooperative Oncology Group performance status and randomly assigned (1:1) to axitinib or placebo titration. The primary endpoint was objective response rate; secondary endpoints included progression-free survival and safety. Predictive factors were analyzed using data from all patients. Results: The objective response rate (95% confidence interval) was 66% (50-80%) vs. 44% (36- 52%) in Japanese and non-Japanese patients, respectively. At the primary analysis, median progression-free survival could not be estimated for Japanese patients, and was 27.6 months (95% confidence interval: 16.6-33.2) in an updated analysis. Hypertension, diarrhea, hand-foot syndrome, dysphonia, hypothyroidism and proteinuria were common adverse events in Japanese patients. Due to a small number of randomized patients, effects of axitinib dose titration could not sufficiently be confirmed among Japanese patients. The multivariate analysis identified time from histopathological diagnosis to treatment and sum of the longest diameter for target lesion at baseline as independent predictive factors for progression-free survival. Conclusions: Axitinib is effective and well tolerated as first-line metastatic renal cell carcinoma therapy in Japanese patients. Predictive factors for axitinib efficacy endpoints identified in this setting warrant further investigation.
AB - Objectives: To conduct Japanese subgroup analyses of a randomized, global Phase II study of axitinib with and without dose titration in first-line metastatic renal cell carcinoma and to explore predictive factors for axitinib efficacy in first-line metastatic renal cell carcinoma. Methods: The data included 44 Japanese and 169 non-Japanese treatment-naïve patients with metastatic renal cell carcinoma. Patients received twice-daily axitinib 5mg during a 4-week lead-in period. Patients who met the pre-defined randomization criteria were stratified by Eastern Cooperative Oncology Group performance status and randomly assigned (1:1) to axitinib or placebo titration. The primary endpoint was objective response rate; secondary endpoints included progression-free survival and safety. Predictive factors were analyzed using data from all patients. Results: The objective response rate (95% confidence interval) was 66% (50-80%) vs. 44% (36- 52%) in Japanese and non-Japanese patients, respectively. At the primary analysis, median progression-free survival could not be estimated for Japanese patients, and was 27.6 months (95% confidence interval: 16.6-33.2) in an updated analysis. Hypertension, diarrhea, hand-foot syndrome, dysphonia, hypothyroidism and proteinuria were common adverse events in Japanese patients. Due to a small number of randomized patients, effects of axitinib dose titration could not sufficiently be confirmed among Japanese patients. The multivariate analysis identified time from histopathological diagnosis to treatment and sum of the longest diameter for target lesion at baseline as independent predictive factors for progression-free survival. Conclusions: Axitinib is effective and well tolerated as first-line metastatic renal cell carcinoma therapy in Japanese patients. Predictive factors for axitinib efficacy endpoints identified in this setting warrant further investigation.
KW - Axitinib
KW - Japanese
KW - Molecular targeted therapy
KW - Randomized clinical trial
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85014409542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014409542&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyw103
DO - 10.1093/jjco/hyw103
M3 - Article
AN - SCOPUS:85014409542
SN - 0368-2811
VL - 46
SP - 1031
EP - 1041
JO - Japanese journal of clinical oncology
JF - Japanese journal of clinical oncology
IS - 11
ER -